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ABSTRACT
Background: Concurrent cardiac diseases are frequent
among elderly patients and invite simultaneous
treatment to ensure an overall favourable patient
outcome.
Aim: To investigate the feasibility of combined single-
session percutaneous cardiac interventions in the era
of transcatheter aortic valve implantation (TAVI).
Methods: This prospective, case–control study
included 10 consecutive patients treated with TAVI, left
atrial appendage occlusion and percutaneous coronary
interventions. Some in addition had patent foramen
ovale or atrial septal defect closure in the same
session. The patients were matched in a 1:10 manner
with TAVI-only cases treated within the same time
period at the same institution regarding their baseline
factors. The outcome was validated according to the
Valve Academic Research Consortium (VARC) criteria.
Results: Procedural time (126±42 vs 83±40 min,
p=0.0016), radiation time (34±8 vs 22±12 min,
p=0.0001) and contrast dye (397±89 vs 250±105 mL,
p<0.0001) were higher in the combined intervention
group than in the TAVI-only group. Despite these
drawbacks, no difference in the VARC endpoints was
evident during the in-hospital period and after 30 days
(VARC combined safety endpoint 32% for TAVI only
and 20% for combined intervention, p=1.0).
Conclusions: Transcatheter treatment of combined
cardiac diseases is feasible even in a single session in
a high-volume centre with experienced operators.
INTRODUCTION
Percutaneous cardiac interventions, by their
less invasive nature, enhance patient
comfort, accelerate recovery time and
shorten hospitalisation duration. They have
proven to be a valid alternative to open heart
surgery for different patient and disease
subsets. This becomes particularly true
among patients with coexisting cardiac dis-
eases necessitating complex combined surgi-
cal management which puts them at an
additional operative risk.1 2 With the intro-
duction of transcatheter aortic valve implant-
ation (TAVI), a long neglected population of
surgically high-risk and inoperable patients
gained access to effective treatment for aortic
valve stenosis.3 Frequently, however, these
elderly patients have concurrent coronary
artery disease and/or atrial ﬁbrillation,
which are both associated with an independ-
ent adverse prognosis.4–6 The management
of these patients should therefore cover con-
current heart diseases to ensure an overall
favourable outcome after TAVI.7 Staged or
simultaneous percutaneous coronary inter-
ventions (PCI) and TAVI have been shown to
be safe and feasible in different series.8 9 We
recently described a successful ﬁrst case of
simultaneous TAVI, PCI and percutaneous
device closure of the left atrial appendage
(LAA).10 LAA occlusion has been demon-
strated to be at least equally effective to long-
term warfarin therapy in preventing systemic
embolism among atrial ﬁbrillation patients11
and is commonly used as a substitute for
anticoagulation among selected patients not
suitable for chronic anticoagulation.12 On
the other hand, patent foramen ovale (PFO)
and atrial septal defects (ASD) are a docu-
mented source for systemic emboli13 and
their percutaneous closure is feasible and
effective in reducing paradoxical embol-
ism.14–17 We sought to investigate the feasibil-
ity of simultaneous cardiac interventions
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including TAVI, PCI and LAA occlusion with or without
PFO/ASD closure in an elderly comorbid population.
METHODS
Patient population and justification of combined
procedures
Ten consecutive cases were selected from a cohort of
400 patients with severe aortic stenosis allocated to TAVI
by the decision of the heart team at the Swiss
Cardiovascular Center of the Bern University Hospital
between 2009 and 2012. Data were entered into a pro-
spective registry and analysed according to the criteria
of the Valve Academic Research Consortium (VARC).18
Patient characteristics were compared with a pool of 100
case–control patients to match every patient with a com-
bined intervention to a control according to the Society
of Thoracic Surgeons (STS) score. Given the prospective
cohort study character, there were no formal exclusion
criteria. The Bern TAVI registry is part of the Swiss TAVI
registry and has been approved by the local and national
ethics committees. The Bern registry for LAA occlusion
is also approved by the local ethics committee. For each
of the combined interventions, dedicated forms listing
potential adverse events, that is, the risk of the respective
procedure, were provided. With regard to the risk/
beneﬁt ratio of combined versus staged interventions
and especially under the aspect of avoiding several
hospitalisations and general anaesthesia, the combined
approach was deemed patient friendly without increas-
ing complications and therefore recommended to the
selected patients of this study.
Data acquisition
Demographic and clinical characteristics, procedural
data, adverse events and outcome data of in-hospital and
follow-up periods were systematically collected. After 1
and 3–4 months, a standardised follow-up examination
was performed. After 3–4 months, in addition to clinical
and neurological examination, a transesophageal echo-
cardiography (TEE) was performed to ensure correct
seating and freedom of relevant thrombi of the LAA
closure device. All events underwent adjudication by a
team of an independent cardiac surgeon and an inde-
pendent interventional cardiologist. Outcome is
reported according to the VARC criteria.
Combined interventions
Beforehand, coronary angiography with invasive haemo-
dynamic assessment, CT angiography (CTA) and TEE
for aortic root assessment and exclusion of LAA thrombi
were performed. Three of the 10 cases were transmitted
live to international interventional courses. If indicated
by angiographic stenosis degree, PCI was performed ﬁrst
by transfemoral access with 5 or 6 Fr guiding catheters
and exclusively using drug-eluting stents (DES), which
was the case in 6 of the 10 combined patients. Two did
not suffer from CAD and in two, the CAD was treated
earlier in a separate procedure. Next, TAVI was per-
formed under mild sedoanalgaesia and inguinal local
anaesthesia only via transfemoral access. A single or
both femoral arteries were accessed and a suture-based
vascular closure device preinstalled on the respective
side of access for TAVI. Aortic stenosis was crossed using
an Amplatzer left diagnostic catheter and a straight
tipped wire. Via a stiff wire, balloon aortic valvuloplasty
under rapid pacing (180/min) was performed. After
advancement of a 16–20 F femoral sheath, the Edwards
Sapien bioprosthesis (balloon-expandable titanium
frame containing bovine pericardial leaﬂets) or
Medtronic Corevalve bioprosthesis (self-expandable
nitinol frame containing porcine pericardial leaﬂets in
supra-annular position) was deployed. Selection of the
device size was based on previous aortic root assessment
by TEE, CTA or angiography. After TAVI, LAA exclusion
and septal closure procedures followed on. In all cases
the ﬁrst generation Amplatzer Cardiac Plug (ACP) was
used. Similar to TAVI, LAA occlusion was performed in a
Figure 1 Representative course
of action in case 2.
Figure 2 End result in case 2.
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frugal manner without general anaesthesia or TEE guid-
ance, that is, under ﬂuoroscopy only: after accessing the
left atrium through a trans-septal puncture or passage
through a pre-existing PFO or ASD, the device size was
selected based on biplane angiography of the LAA
through the 9–13 F delivery sheath. After deployment,
sustained tugging with the delivery cable tested ACP
seating within the LAA and another biplane left atrial
angiography was performed prior to the release. In case
of unsatisfactory positioning or anchoring, the plug was
recaptured and redeployed in a different angle or
changed for a more suitable sized device. On the way
back, a pre-existing PFO or ASD was closed by the same
cable and delivery sheath using Amplatzer PFO or ASD
occluders. After closure of the percutaneous arterial
access and slight compression of the femoral vein,
patients were posthydrated with normal saline according
to the standard protocol and transferred to a cardiac
intermediate care ward (see ﬁgures 1 and 2 for a repre-
sentative course of action in case 2). Restart of oral
anticoagulation was omitted. A dose of 75 mg of clopido-
grel daily for 3–6 months and 100 mg of acetylsalicylic
acid were prescribed indeﬁnitely. For documentation of
aortic bioprosthesis performance and exclusion of
device displacement or pericardial effusion, transthor-
acic echocardiography was performed on day one after
intervention and after 30 days. The patients were dis-
charged on postprocedure days 3–7.
Table 1
Individual case description
(1) 78-year-old man AS, CAD, AFib Rationale: high risk of bleeding/avoidance of triple therapy
TAVI: Medtronic Corevalve 29 mm
PCI: Promus 2.75×23 mm (LCX), Xience 3.0×12 (LAD), SYNTAX score: 14
LAAO: Amplatzer Cardiac Plug 20 mm
(2) 84-year-old woman, AS, CAD, ASD,
AFib
Rationale: high risk of bleeding/avoidance of triple therapy
TAVI: Medtronic Corevalve 26 mm
PCI: Biomatrix 3.0×18 (LAD), SYNTAX score: 12
ASD closure: Amplatzer Septal Occluder 24 mm
LAAO: Amplatzer Cardiac Plug 24 mm
(3) 84-year-old woman, AS, CAD, PFO,
AFib
Rationale: high risk of bleeding/avoidance of triple therapy
TAVI: Edwards Sapien XT 26 mm
PCI: Resolute 3.0×18 mm (RCA) LAAO: Amplatzer Cardiac Plug 22 mm, SYNTAX
score: 6
PFO closure: Amplatzer PFO Occluder 25 mm
(4) 88-year-old woman, AS, CAD, AFib Rationale: history of GI-bleeding/avoidance of triple therapy
TAVI: Edwards Sapien XT 23 mm, SYNTAX score: 35
LAAO: Amplatzer Cardiac Plug 20 mm
(5) 85-year-old woman, AS, AFib Rationale: history of GI-bleeding/avoidance of triple therapy
TAVI: Edwards Sapien XT 26 mm, SYNTAX score: 0
LAAO: Amplatzer Cardiac Plug 28 mm
(6) 83-year-old man, AS, CAD, AFib Rationale: history of GI bleeding/avoidance of triple therapy
TAVI: Medtronic Corevalve 31 mm
PCI (prior to TAVI and LAAO): Xience Prime ×4 (RCA, LAD), SYNTAX score: 12
LAAO: Amplatzer Cardiac Plug 20 mm
Cerebral Protection with Claret
(7) 79-year-old man, AS, CAD, AFib Rationale: high risk of bleeding/avoidance of triple therapy
TAVI: Medtronic Corevalve 29 mm
PCI (prior to TAVI and LAAO): Orsiro ×2 (LCX), SYNTAX score: 16
LAAO: Amplatzer Cardiac Plug 22 mm
(8) 80-year-old woman, AS, CAD, PFO,
AFib
Rationale: high risk of bleeding/avoidance of triple therapy
TAVI: Medtronic Corevalve 26 mm, SYNTAX score: 0
LAAO: Amplatzer Cardiac Plug 16 mm
PFO closure: Amplatzer PFO Occluder 25 mm
(9) 63-year-old man, AS, CAD, AFib Rationale: history of GI-bleeding/avoidance of triple therapy
TAVI: Edwards Sapien XT 23 mm, SYNTAX score: 24
LAAO: Amplatzer Cardiac Plug 22 mm
(10) 89-year-old woman, AS, CAD, AFib Rationale: high risk of bleeding / avoidance of triple therapy
TAVI: Edwards Sapien XT 23 mm
PCI: Orsiro ×2 (LAD), SYNTAX score: 30
LAAO: Amplatzer Cardiac Plug 26 mm
AFib, atrial fibrillation; AS, aortic valve stenosis; ASD, atrial septal defects; CAD, coronary artery disease; LAAO, left atrial appendage
occlusion; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; PCI, percutaneous coronary interventions; TAVI,
transcatheter aortic valve implantation.
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Matching and statistical analysis
For every combined case, 10 controls were selected from
the database according to the most ﬁtting STS score.
Since the STS score contains all relevant patient
characteristics and has been shown to be very accurate
in predicting a 30-day outcome also in TAVI patients, it
was deemed appropriate for matching. Continuous vari-
ables are presented as mean±SD and were compared
using the unpaired Mann-Whitney U test. Categorical
data are expressed as frequency (percentages) and were
compared with Fisher’s exact test. All tests and CIs are
two-sided, and an α level of 0.05 was chosen to deter-
mine the statistical signiﬁcance of differences. Analyses
were performed using GraphPad Prism 6 (http://www.
graphpad.com).
RESULTS
Baseline characteristics and matching
Table 1 provides a brief description of each individual
case and baseline characteristics are summarised in
table 2. The rationale for LAA occlusion along with
TAVI (5 with CoreValve, 5 with Edwards Sapien XT) and
PCI were high bleeding risk in six and prior major
bleeding in four patients. In 3 of the 10 patients, PFO
closure (2) and ASD closure (1) were performed in add-
ition. Matching could be performed with an excellent
agreement (mean difference in STS score between cases
and control groups: 0.37±1.01).
Periprocedural and 1-month follow-up
Expectedly, procedure time, use of contrast and radi-
ation was higher in the combined group when com-
pared with the controls with TAVI only. Despite these
drawbacks, no difference in the VARC endpoints was
evident during the in-hospital period and after 30 days
(see tables 3 and 4).
Three-month follow-up
Table 5 illustrates the 3–4 months clinical and echocar-
diographic follow-up data. No patient was lost to
follow-up. All patients but one (sudden cardiac death
118 days after the index procedure) were alive without
Table 2
Baseline characteristics TAVI matched cases (n=100) Combined interventions (n=10) p Value
Age (years) 83.5±5.8 82.3±7.8 0.67
BMI (kg/m2) 24.8±4.8 26.1±4.0 0.28
CHADS2 score (points) 2.6±0.8 2.8±1.5 0.84
Creatinine clearance (mL/min) 44.4±19 41.8±13 0.81
Female gender 59/100 (59%) 6/10 (60%) 1
Coronary artery disease 65/100 (65%) 9/10 (90%) 0.16
Prior myocardial infarction 14/100 (14%) 4/10 (40%) 0.23
Prior CABG 15/100 (15%) 3/10 (30%) 0.21
Prior stroke 12/100 (12%) 1/10 (10%) 1
LV-EF (%) 49±17 59±10 0.12
AVA (cm2) 0.5±0.2 0.6±0.2 0.38
Mean transvalvular aortic gradient 41±18 54±17 0.055
Logistic EURO score I (%) 30.9±16.6 22.3±11.1 0.17
Logistic EURO score II (%) 11.3±8.1 11.2±7.3 0.90
STS score (%) 10.5±5.7 10.9±6.6 0.98
Atrial fibrillation 37/100 (37%) 10/10 (100%) 0.0001
AVA, aortic valve area; BMI, body mass index; CABG, coronary artery bypass graft; CHADS, congestive heart failure, age, diabetes, stroke;
LV-EF, left ventricular ejection fraction; TAVI, transcatheter aortic valve implantation.
Table 3
Periprocedural outcomes TAVI matched cases (n=100) Combined interventions (n=10) p Value
Procedure time (min) 83±40 126±42 0.0016
Fluoroscopy time (min) 22±12 34±8 0.0001
Contrast dye (mL) 250±105 397±89 <0.0001
Successful device implantation 99/100 (99%) 10/10 (100%) 1
VARC access site complication (all) 26/100 (26%) 2/10 (20%) 1
Need for femoral covered stent 20/100 (20%) 1/10 (10%) 0.68
VARC bleeding (all) 45/100 (45%) 4/10 (40%) 1
VARC kidney injury (all) 17/100 (17%) 2/10 (20%) 0.68
VARC kidney injury stage 3 4/100 (4%) 2/10 (20%) 0.09
TAVI, transcatheter aortic valve implantation; VARC, Valve Academic Research Consortium.
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events. Aortic bioprosthesis function was normal in all
patients with no or mild paraprosthetic aortic regurgita-
tion. No residual shunts or thrombi were seen after
LAAO or PFO/ASD closure.
DISCUSSION
Surgical aortic valve replacement is associated with an
unadjusted operative mortality of 3% and reaches 5%
when combined with CABG. The surgical mortality rate
Table 4
1-Month follow-up (VARC endpoints) TAVI matched cases (n=100) Combined interventions (n=10) p Value
Death 11/100 (11%) 0/10 (0%) 0.59
Cardiac death 10/100 (10%) 0/10 (0%) 0.59
Myocardial infarction 0/100 (0%) 0/10 (0%) 1
Stroke (all) 4/100 (4%) 0/10 (0%) 1
MACE 14/100 (14%) 0/10 (0%) 0.36
VARC combined safety endpoint 32/100 (32%) 3/10 (20%) 1
TAVI, transcatheter aortic valve implantation; VARC, Valve Academic Research Consortium.
Table 5
3-Month follow-up
(1) 78-year-old man, AS, CAD, AFib Status: free from embolic events
TAV: normal function, moderate AR
ACP: correct position; sufficient LAA exclusion, no shunt and no thrombus
Tx: ASA, clopidogrel and no anticoagulation
(2) 84-year-old woman, AS, CAD, ASD, AFib Status: free from embolic events
TAV: normal function, moderate AR
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
(3) 84-year-old woman, AS, CAD, PFO, AFib Status: free from embolic events
TEE denied
Tx: ASA, clopidogrel, no anticoagulation
(4) 88-year-old woman, AS, CAD, AFib Status: died from sudden cardiac death 118 days after Intervention
TEE not performed
(5) 85-year-old woman, AS, AFib Status: free from embolic events
TEE denied
Tx: clopidogrel, no anticoagulation
(6) 83-year-old man, AS, CAD, AFib Status: free from embolic events
TAV: normal function, mild AR
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
(7) 79-year-old man, AS, CAD, AFib Status: free from embolic events
TAV: normal function, mild AR
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
(8) 80-year-old woman, AS, CAD, PFO, AFib Status: free from embolic events
TAV: normal function, mild AR
PFO: correct position; no residual shunt, no thrombus
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
(9) 63-year-old man, AS, CAD, AFib Status: free from embolic events
TAV: normal function, no AR
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
(10) 89-year-old woman, AS, CAD, AFib Status: free from embolic events
TAV: normal function, no AR
ACP: correct position; sufficient LAA exclusion, no shunt, no thrombus
Tx: ASA, clopidogrel, no anticoagulation
ACP, Amplatzer cardiac plug; AS, aortic valve stenosis; ASA, acetylsalicylic acid; AFib, atrial fibrillation; CAD, coronary artery disease; LAA,
left atrial appendage; PFO, patent foramen ovale; TAV, transcatheter aortic valve; TEE, transesophageal echocardiography.
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rises exponentially in patients above 80 years.19 Rates of
thromboembolic complications (related to atrial ﬁbrilla-
tion and paradoxical embolism) as well as spontaneous
and iatrogenic bleeding tendency increase with advan-
cing age as reﬂected in contemporary risk stratiﬁcation
systems. Octogenarians are reluctant to seek medical
care and physicians are hesitant to apply appropriate
therapeutic strategies. With the introduction of various
catheter-based percutaneous structural heart disease
interventions, this hitherto neglected morbid population
gains access to guideline-based medical care.
In our series, all patients had severe aortic stenosis
(which was treated by TAVI) and eight of them had sig-
niﬁcant coronary artery disease (of whom six were
treated with DES along with TAVI). Regarding the time
point of treating concomitant CAD, this should be
treated at one time with the respective procedure of
aortic valve replacement, irrespective of the approach
selected by the heart team beforehand (ie, surgical
revascularisation and SAVR or PCI and TAVI).
On top of that they had atrial ﬁbrillation, which would
have required chronic anticoagulation (CHADS2 score
for all patients >1) in addition to dual antiplatelet
therapy recommended for coronary stents for at least
3–6 months. Although newer data suggest safety and efﬁ-
cacy of a combination of clopidogrel and oral anticoagu-
lation, many patients still receive triple oral
antithrombotic therapy, which carries a signiﬁcantly
higher risk of bleeding than dual antiplatelet therapy20 21
while dual antiplatelet therapy alone is less effective than
oral anticoagulation in preventing thromboembolic com-
plications.22 LAA closure provides stroke prevention
equal to that of warfarin without bleeding risk.11
Although the value of PFO/ASD closure as a primary pre-
vention measure against paradoxical embolism is not
clear, we performed this as the ﬁnal step of the combined
interventions among these patients because of the
general ease of this intervention in the setting of LAA
closure, with the appropriate gear already in place.
Compared with their matched counterparts receiving
TAVI only, the combined intervention cases suffered
from a higher burden of comorbidities and their proce-
dures were longer and consumed more contrast dye. In
spite of these disadvantages, the immediate and
intermediate-term outcomes were not different between
groups as judged by the VARC criteria. Alternatively to
this single session approach a staged approach may
reduce dye usage per session and hence transient kidney
injury is occasionally encountered. However, this occurs
at the expense of reduced patient comfort and compli-
ance, which may lead to refraining from planned com-
plementary interventions. Obviously, the power of the
present study is too low to address the safety of increased
contrast use. The combined procedures were all per-
formed without general anaesthesia and without TEE
guidance. Combining therapeutic measures becomes
even more compelling if general anaesthesia and TEE
guidance are deemed necessary.
Limitations
The present study has several limitations: first, the pre-
sented data reﬂect the experience of a high-volume ter-
tiary care cardiology department. Second, due to the
retrospective and observational character of the study,
there was no prospective randomisation of cases,
although the baseline STS score showed good agreement
between the two groups after the performed matching
process. Moreover, due to the manual matching a poten-
tial bias could have been introduced as compared with an
automated process. Furthermore, the number of the
reported combined cases and the respective event rates
are low. Therefore, the issues of safety and net clinical
beneﬁt cannot be cleared deﬁnitively on the basis of the
present study.
Conclusions
Transcatheter treatment of combined cardiac diseases is
feasible even in a single session in high-volume centres
with experienced operators. However, for deﬁnite proof
of safety comparable to TAVI-only procedures, larger
numbers of combined procedures or ideally, a controlled,
prospective randomised study would be desirable.
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